通过向EZH2来治疗人类癌症.
Mengfei Xu1,2, Chunyan Xu1, Rui Wang1,2
1The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510120, China.
Genes & diseases
|March 3, 2025
概括
增强性凝血同源2 (EZH2) 是一种在瘤中过度表达的瘤基因,驱动癌症的进展. 针对EZH2对于癌症治疗至关重要,尽管临床应用面临挑战.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- 增强性凝血同源2 (EZH2) 是一种表观遗传调节剂,在各种瘤中过度表达.
- EZH2充当瘤基因,促进瘤的发生,发展,入侵,迁移,耐药性,并影响抗瘤免疫力.
- 癌症中EZH2表达的升高是由合作的转录因子和RNAs促进的.
研究的目的:
- 为了澄清在癌症治疗中准EZH2的关键重要性.
- 总结一下针对性EZH2抑制剂的当前研究环境.
- 提供关于EZH2抑制剂在瘤学中的潜在未来应用的见解.
主要方法:
- 本综述综合了关于EZH2在癌症中的作用的当前研究.
- 文献综述侧重于EZH2的功能,过度表达机制和治疗向.
- 对现有和潜在的EZH2抑制剂及其临床挑战的分析.
主要成果:
- 作为癌基因,EZH2在癌症进展和转移中发挥着多方面的作用.
- 有几个因素导致恶性瘤中EZH2过度表达.
- 针对EZH2具有显著的治疗潜力,尽管目前的临床障碍.
结论:
- 向EZH2是癌症治疗的一个有前途的策略,因为它具有致癌功能.
- 克服EZH2抑制剂临床应用中的挑战对于有效的癌症治疗至关重要.
- 对EZH2抑制剂的进一步研究可能为各种癌症打开新的治疗途径.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K


